Gilead Sciences and Pharmstandard Signed a Memorandum of Understanding for the Localization and Distribution of Veklury™ (remdesivir*) in Russia


— Gilead has applied to the Ministry of Health of Russia for approval for its COVID-19 therapy in the Russian Federation —

Moscow, September 18, 2020 — Gilead Sciences and Pharmstandard signed a Memorandum of Understanding that lays the foundation for their partnership to market, supply, localize, and distribute Veklury™ (remdesivir), a drug product for the treatment of patients with COVID-19, in the territory of Russia.

"Our primary task in times as challenging as the COVID-19 pandemic is to provide the patients and the healthcare system with solutions that can change the course of the disease and reduce the burden on healthcare systems. With this responsibility in mind, we strive to make remdesivir available in every country. Joining forces with Pharmstandard will let us increase the availability of the drug for Russian patients and, thus, make another step towards victory over the pandemic," says Igor Rukavishnikov, the General Manager of Gilead Russia.

"At the moment, the struggle against the COVID-19 pandemic is of tremendous importance for the whole world, and, the way we see it, interaction and cooperation play an essential role in this process. Our long-term partnership with Gilead on the implementation of joint projects for the localization of therapies for socially significant diseases in Russia has been successfully developing, and we are ready to offer our manufacturing resources, experience, and expertise to expand the access to the necessary drug therapy for patients with COVID-19," says Grigory Potapov, CEO of Pharmstandard JSC.

Remdesivir has been approved for emergency use for the treatment of COVID-19 in the United States, has been registered in Japan, Taiwan, Singapore, the United Arab Emirates, India, and has become the first drug approved for the treatment of COVID-19 in the European Union.

About Veklury™ (remdesivir)

Veklury™ (remdesivir) is an antiviral drug that is being tested in numerous international clinical trials. The drug has been registered and recommended for use only in some countries. Where remdesivir has not been registered by the national healthcare authorities, it remains an investigational drug product. The safety and efficacy of remdesivir for the treatment of patients with COVID-19 is currently being evaluated.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead's response to the coronavirus outbreak, please visit the company's website:

About Pharmstandard

Pharmstandard is a leading Russian pharmaceutical company that develops and manufactures high quality, affordable, and innovative pharmaceutical products to meet the needs of patients and the Russian healthcare system. The company manufactures more than 450 drug products, including all dosage forms, strengths, and products intended for export. Over 140 of them are included in the List of Vital and Essential Drugs. The company's pharmaceutical portfolio includes drugs for the treatment of cardiovascular diseases, diabetes mellitus, growth hormone deficiency, metabolic disorders, respiratory diseases, oncological, gastroenterological, neurological, and infectious diseases, as well as a range of other diseases.

The company's pharmaceutical manufacturing facilities are located in Kursk, Ufa, Tomsk, and Volginsky settlement (Vladimir region). The pharmaceutical production is organized in compliance with the requirements of the Good Manufacturing Practice Guidelines, which is verified by the GMP compliance certificates.

Pharmstandard is one of the leaders in localizing the production of innovative drug products in Russia under partnership agreements with international pharmaceutical companies. The company's products are supplied throughout the Russian Federation and abroad.

*The drug has not been registered in the Russian Federation yet

Back Print out

Media Contacts

Marina Shurkina

Press & Public Relations Unit

+7 (495) 970 0032

Информация на сайте предназначена исключительно для медицинских работников.

Подтвердите, пожалуйста, являетесь ли Вы медицинским работником.

Если Вы не являетесь медицинским работником, пожалуйста, покиньте данный раздел сайта.


1.На сайте представлена информация о рецептурных препаратах, их свойствах, способах применения и возможных противопоказаниях исключительно специалистам здравоохранения (лицам, имеющим высшее или среднее специальное медицинское образование).

2. Если Вы являетесь специалистом здравоохранения и хотите получить информацию с данного раздела сайта, Вам необходимо подтвердить ваш статус специалиста здравоохранения.

3. В случае если Вы не являетесь специалистом здравоохранения, но в нарушение настоящих условий подписываете данное соглашение, сайт Компании не несет ответственности за возможные отрицательные последствия, возникшие в результате самостоятельного использования Вами информации с сайта, без предварительной консультации со специалистом. Вы делаете это самостоятельно и осознанно, понимая, что применение рецептурных препаратов возможно только после предварительной консультации со специалистом здравоохранения.

4. Информация о рецептурных препаратах, представленная на данном разделе сайте, предназначена исключительно для ознакомления с препаратами и не является руководством для самостоятельной диагностики или лечения, и не служит в качестве медицинских советов или рекомендаций. Сайт не несет ответственности за возможный ущерб, нанесенный Вашему здоровью в случае самовольного лечения, проводимого на основании применения рецептурных препаратов (без предварительной консультации со специалистом). Настоящим я подтверждаю, что являюсь специалистом здравоохранения и подтверждаю своё согласие с тем, что применение рецептурных препаратов возможно только после предварительной консультации со специалистом.